Elevated baseline levels of CgA and their relative increase within the first year of observation have been identified as unfavorable predictors of overall survival, indicating the potential of CgA as a prognostic marker in patients with pancreatic and midgut neuroendocrine tumors undergoing peptide receptor radionuclide therapy with octreotide [43]. Here, CGA is linked to neuroendocrine neoplasm.